Filing Flows › Health Care › Pyxis Oncology (PYXS)
Pyxis Oncology (PYXS) earnings and revenue breakdown
Latest: Q4 2025 · 10-K filed Mar 23, 2026 · Pyxis Oncology (PYXS) Q4 2025 earnings results →
Q4 2025 164¢ of every $1 of revenue lost · operating margin -165.7%
Pyxis Oncology made $11.0M in Q4 2025. Operating margin -165.7%, net loss $18.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 23, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $11.0M in Q4 2025.
Operating costs exceeded revenue by $18.3M, an operating margin of -165.7%. The quarter ended with a net loss of $18.1M.
Operating cash flow was −$10.4M. Non-cash charges added back $2.9M of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items added $2.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 10-K | Mar 23, 2026 | $11.0M | — | -165.7% | −$18.1M | −$10.4M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $2.8M | — | -700.4% | −$18.4M | −$17.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Pyxis Oncology
Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Our lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational novel antibody-drug conjugate (ADC) that uniquely targets the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the extracellular matrix (ECM) in the tumor microenvironment (TME).
In its own words, from its 10-K, filed Mar 23, 2026.
Pyxis Oncology against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -165.7% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PYXS Pyxis Oncology | Q4 2025 | $11.0M | — | -165.7% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Pyxis Oncology 10-K on SEC EDGAR · CIK 1782223 · Pharmaceutical Preparations
13F: who owns PYXS and who is buying
More on PYXS
History
Every quarter: Q4 2025 results · Q2 2025 results